As of February 6, 2026
Ethical drug
| Development code | Generic name | Stage | Indications | Formulation | Remarks <Development country> |
|---|---|---|---|---|---|
| RGB-19 | tocilizumab | Filed | Rheumatoid Arthritis | Injection | Biosimilar Licensed-in from Gedeon Richter Plc. <Japan> |
| FYU-981 | dotinurad | Phase III | Gout and hyperuricemia (pediatric indication) | Oral | Co-development with FUJI YAKUHIN Co., Ltd. <Japan> |
| HLC-001 | - | Phase III | Non-infectious pulmonary complications after hematopoietic stem cell transplantation | Injection | Cellular therapy product Co-development with Human Life CORD Japan, Inc. <Japan> |
| MD-352 | dienogest formulation | Phase II/III | Dysmenorrhea | Oral | In-house development <Japan> |
| MD-712 | treprostinil | Phase II/III | Pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease | Dry Powder Inhaler | Licensed-in from United Therapeutics Corporation In-house development <Japan> |
| MND-21 | icosapent | Approved | Severe hypertriglyceridemia | Oral | Collaboration on development with Marubeni Pharmaceuticals (Suzhou) Co., Ltd. (formerly Sumitomo Pharma (Suzhou) Co., Ltd.) <China> |
Medical device
| Development code <Product name> |
Stage | Intended use or indications | Remarks <Development country> |
|---|---|---|---|
| dMD-002 | Therapeutic confirmatory study | Repair of Cavernous nerve injury | In-house development <Japan> |
| dMD-003 | Therapeutic confirmatory study | Prevention of Post-operative adhesion | In-house development <Japan> |